Sherif S. Farag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sherif S. Farag has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Andrew J. Carroll
From The Ohio State University, Columbus, OH; The Cancer and Leukemia Group B Statistical Center; Duke University, Durham; Wake Forest University, Winston-Salem, NC; Dana-Farber Cancer Institute, Boston, MA; University of Alabama at Birmingham, Birmingham, AL; North Shore University Hospital, Manhasset; Roswell Park Cancer Institute, Buffalo, NY; University of Maryland Cancer Center, Baltimore, MD; University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI
3 shared publicationsMark J. Pettenati
From The Ohio State University, Columbus, OH; The Cancer and Leukemia Group B Statistical Center; Duke University, Durham; Wake Forest University, Winston-Salem, NC; Dana-Farber Cancer Institute, Boston, MA; University of Alabama at Birmingham, Birmingham, AL; North Shore University Hospital, Manhasset; Roswell Park Cancer Institute, Buffalo, NY; University of Maryland Cancer Center, Baltimore, MD; University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI
3 shared publications- Richard A. Larson
University of Chicago, Chicago, IL
3 shared publications Amy S. Ruppert
From The Ohio State University, Columbus, OH; The Cancer and Leukemia Group B Statistical Center; Duke University, Durham; Wake Forest University, Winston-Salem, NC; Dana-Farber Cancer Institute, Boston, MA; University of Alabama at Birmingham, Birmingham, AL; North Shore University Hospital, Manhasset; Roswell Park Cancer Institute, Buffalo, NY; University of Maryland Cancer Center, Baltimore, MD; University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI
2 shared publicationsBayard L. Powell
From The Ohio State University, Columbus, OH; The Cancer and Leukemia Group B Statistical Center; Duke University, Durham; Wake Forest University, Winston-Salem, NC; Dana-Farber Cancer Institute, Boston, MA; University of Alabama at Birmingham, Birmingham, AL; North Shore University Hospital, Manhasset; Roswell Park Cancer Institute, Buffalo, NY; University of Maryland Cancer Center, Baltimore, MD; University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI
2 shared publications- Clara Derber Bloomfield
The Ohio State University Comprehensive Cancer Center, Columbus, USA
2 shared publications
Latest Publications
- Open Access
- 14 February 2005
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 35 (7) , 653-661
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia
- 14 February 2005
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 35 (7) , 653-661
Open AccessHigh-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia
- 20 January 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (3) , 482-493
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
Purpose Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML). Patients and Methods In 490 patients, induction included cytarabine and daunorubicin (AD) or cytarabine and escalated doses of daunorubicin and etoposide ± PSC-833 (ADE/ADEP). Intensification included one cycle of high-dose cytarabine (HDAC) followed by etoposide/cyclophosphamide and mitoxantrone/diaziquone (group I), three HDAC cycles (group II), four intermediate-dose cytarabine (IDAC) or HDAC cycles (group III), or one HDAC/etoposide cycle and autologous stem-cell transplantation (ASCT; group IV). Results Of 350 patients receiving AD, 73% achieved complete remission (CR), compared with 82% of 140 receiving ADE/ADEP (P = .04). Splenomegaly was associated with a lower CR rate (P < .001), and ADE/ADEP, with a higher CR rate in younger patients (P = .005). The 5-year disease-free survival (DFS) rate was 28% each for intensification groups I and II, compared with 41% and 45% for groups III and IV, respectively (P = .02). The 5-year cumulative incidence of relapse (CIR) was 62% and 67% for groups I and II, respectively, compared with 54% and 44% for groups III and IV, respectively (P = .049). The type of postremission intensification remained significant for DFS and CIR in multivariable analysis. Conclusion In younger adults with normal cytogenetics AML, splenomegaly predicts a lower CR rate, and the postremission strategies of either four cycles of I/HDAC or one cycle of HDAC/etoposide followed by ASCT are associated with improved DFS and reduced relapse compared with therapies that include fewer cycles of cytarabine or no transplantation.
- 20 January 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (3) , 482-493
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
Purpose Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML). Patients and Methods In 490 patients, induction included cytarabine and daunorubicin (AD) or cytarabine and escalated doses of daunorubicin and etoposide ± PSC-833 (ADE/ADEP). Intensification included one cycle of high-dose cytarabine (HDAC) followed by etoposide/cyclophosphamide and mitoxantrone/diaziquone (group I), three HDAC cycles (group II), four intermediate-dose cytarabine (IDAC) or HDAC cycles (group III), or one HDAC/etoposide cycle and autologous stem-cell transplantation (ASCT; group IV). Results Of 350 patients receiving AD, 73% achieved complete remission (CR), compared with 82% of 140 receiving ADE/ADEP (P = .04). Splenomegaly was associated with a lower CR rate (P < .001), and ADE/ADEP, with a higher CR rate in younger patients (P = .005). The 5-year disease-free survival (DFS) rate was 28% each for intensification groups I and II, compared with 41% and 45% for groups III and IV, respectively (P = .02). The 5-year cumulative incidence of relapse (CIR) was 62% and 67% for groups I and II, respectively, compared with 54% and 44% for groups III and IV, respectively (P = .049). The type of postremission intensification remained significant for DFS and CIR in multivariable analysis. Conclusion In younger adults with normal cytogenetics AML, splenomegaly predicts a lower CR rate, and the postremission strategies of either four cycles of I/HDAC or one cycle of HDAC/etoposide followed by ASCT are associated with improved DFS and reduced relapse compared with therapies that include fewer cycles of cytarabine or no transplantation.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 6542
Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic stem cell transplantation (ASCT) for acute myeloid leukemia (AML) patients <60 years with normal cytogenetics: A Cancer and Leukemia Group B (CALGB) Study
6542 Background: The optimal post-remission treatment (Rx) of AML patients with normal cytogenetics has not been extensively studied. Methods: We compared the outcome of 4 intensive post-remission treatment in 280 AML patients with normal cytogenetics, median age 44 (range, 18–59) years, who achieved complete remission (CR) on 5 successive front-line CALGB protocols. Patients were in CR after induction treatmen with AC + daunorubicin (D), ACD + etoposide (E) or ACDE + PSC-833. Post-remission intensification included 1 cycle HDAC (3 g/m2) followed by 1 cycle E+cyclophosphamide and 1 cycle mitoxantrone +diaziquone (Rx-I); HDAC for 3 cycles (Rx-II); IDAC (400 mg/m2) for 4 cycles or HDAC for 4 cycles (Rx-III), or HDAC+E followed by HD busulfan/E and ASCT (Rx-IV). IDAC and HDAC x 4 gave similar DFS (P=0.99) and OS (0.81) and were combined (I/HDAC) in further analysis. Median follow-up is 7.4 (range, 2.2–16.6) years. Results: The outcome of an intent-to-treat analysis of post-remission treatment is shown in the table. Multivariable analysis (MVA) controlling for number of induction cycles, age, white cell count and other pre-treatment variables showed that I/HDAC x 4 improved DFS over HDAC x 3 (P=0.01) and Rx-I (P=0.0005), but was similar to ASCT (P=0.20). ASCT also improved DFS over Rx-I (P=0.04). On MVA I/HDAC improved OS only over Rx-I (P=0.02), whereas ASCT did not significantly improve OS relative to Rx-I (P=0.28). Conclusions: In AML patients <60 years with normal karyotype, either 4 cycles of I/HDAC or ASCT improved DFS relative to less intensive post-remission therapy. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 6542
Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic stem cell transplantation (ASCT) for acute myeloid leukemia (AML) patients <60 years with normal cytogenetics: A Cancer and Leukemia Group B (CALGB) Study
6542 Background: The optimal post-remission treatment (Rx) of AML patients with normal cytogenetics has not been extensively studied. Methods: We compared the outcome of 4 intensive post-remission treatment in 280 AML patients with normal cytogenetics, median age 44 (range, 18–59) years, who achieved complete remission (CR) on 5 successive front-line CALGB protocols. Patients were in CR after induction treatmen with AC + daunorubicin (D), ACD + etoposide (E) or ACDE + PSC-833. Post-remission intensification included 1 cycle HDAC (3 g/m2) followed by 1 cycle E+cyclophosphamide and 1 cycle mitoxantrone +diaziquone (Rx-I); HDAC for 3 cycles (Rx-II); IDAC (400 mg/m2) for 4 cycles or HDAC for 4 cycles (Rx-III), or HDAC+E followed by HD busulfan/E and ASCT (Rx-IV). IDAC and HDAC x 4 gave similar DFS (P=0.99) and OS (0.81) and were combined (I/HDAC) in further analysis. Median follow-up is 7.4 (range, 2.2–16.6) years. Results: The outcome of an intent-to-treat analysis of post-remission treatment is shown in the table. Multivariable analysis (MVA) controlling for number of induction cycles, age, white cell count and other pre-treatment variables showed that I/HDAC x 4 improved DFS over HDAC x 3 (P=0.01) and Rx-I (P=0.0005), but was similar to ASCT (P=0.20). ASCT also improved DFS over Rx-I (P=0.04). On MVA I/HDAC improved OS only over Rx-I (P=0.02), whereas ASCT did not significantly improve OS relative to Rx-I (P=0.28). Conclusions: In AML patients <60 years with normal karyotype, either 4 cycles of I/HDAC or ASCT improved DFS relative to less intensive post-remission therapy. No significant financial relationships to disclose.
- 1 July 2004
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 25 (1) , 143-151
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α: A Cancer and Leukemia Group B study
Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) have been associated with an inferior outcome in reported series of largely chemotherapy-treated patients. To date, no study has specifically focused on the prognostic significance of secondary karyotypic abnormalities, detected at the time of diagnosis, in interferon (IFN)-α treated patients. We compared the outcome of 29 newly diagnosed Ph+ CML patients with additional abnormalities to that of 234 sole Ph+ patients, treated on CALGB protocols with IFN-α alone or together with IFN-γ or low-dose cytarabine. Complete and partial cytogenetic responses were achieved in 20 and 19% of sole Ph+ patients, compared to 23 and 18%, respectively, of patients with additional abnormalities (P=1.00). None of 4 patients with ‘high-risk’ secondary abnormalities [+8, +Ph and i(17)(q10)], for whom follow-up cytogenetic samples were available, achieved a cytogenetic response. With a median follow-up of 11.3 years, the median overall survival (OS) was 6.0 years for sole Ph+ patients compared to 7.5 years for patients with additional abnormalities (P=0.70), with corresponding 8-year OS of 36 and 38%, respectively. On multivariable analysis, only age (P<0.001) and white blood cell count (P=0.02) were associated with outcome. We conclude that, with the possible exception of +8, +Ph and i(17)(q10), additional chromosomal abnormalities at diagnosis are not associated with inferior outcome in Ph+ CML patients treated with IFN-α-based therapy.
- 1 July 2004
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 25 (1) , 143-151
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α: A Cancer and Leukemia Group B study
Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) have been associated with an inferior outcome in reported series of largely chemotherapy-treated patients. To date, no study has specifically focused on the prognostic significance of secondary karyotypic abnormalities, detected at the time of diagnosis, in interferon (IFN)-α treated patients. We compared the outcome of 29 newly diagnosed Ph+ CML patients with additional abnormalities to that of 234 sole Ph+ patients, treated on CALGB protocols with IFN-α alone or together with IFN-γ or low-dose cytarabine. Complete and partial cytogenetic responses were achieved in 20 and 19% of sole Ph+ patients, compared to 23 and 18%, respectively, of patients with additional abnormalities (P=1.00). None of 4 patients with ‘high-risk’ secondary abnormalities [+8, +Ph and i(17)(q10)], for whom follow-up cytogenetic samples were available, achieved a cytogenetic response. With a median follow-up of 11.3 years, the median overall survival (OS) was 6.0 years for sole Ph+ patients compared to 7.5 years for patients with additional abnormalities (P=0.70), with corresponding 8-year OS of 36 and 38%, respectively. On multivariable analysis, only age (P<0.001) and white blood cell count (P=0.02) were associated with outcome. We conclude that, with the possible exception of +8, +Ph and i(17)(q10), additional chromosomal abnormalities at diagnosis are not associated with inferior outcome in Ph+ CML patients treated with IFN-α-based therapy.
- 26 January 2004
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 33 (6) , 569-577
Chronic graft-versus-host disease: where do we go from here?
- 26 January 2004
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 33 (6) , 569-577
Chronic graft-versus-host disease: where do we go from here?
- 1 February 2003
- Published by Springer Nature in International Journal of Hematology
- Vol. 78 (1) , 7-17
Biology and clinical impact of human natural killer cells
Natural killer (NK) cells, through elaboration of cytokines and cytolytic activity, are critical to host defense against invading organisms and malignant transformation.Two subsets of human NK cells are identified according to surface CD56 expression. CD56dim cells compose the majority of NK cells and function as effectors of natural cytotoxicity and antibody-dependent cellular cytotoxicity, whereas CD56bright cells have immunomodulatory function through secretion of cytokines. For a long time, NK cells have held promise for cancer immunotherapy because, unlike T-lymphocytes, NK cells can lyse tumor cells without tumor-specific antigen recognition.To date, NK cell therapy, largely focused on in vivo expansion and activation with cytokines, has met with only modest success. However, recent understanding of the importance of NK receptors (NKR) for recognition and lysis of tumor cells while normal cells are spared suggests novel therapeutic strategies.The balance of inhibitory and activating signals through surface receptors that recognize major histocompatibility complex class I and class I-like molecules on target cells determines whether NK cells activate killing. Identification of NKR ligands and their level of expression on normal and neoplastic cells has important implications for the rational design of immunotherapy strategies for cancer.We review recent development in the biology and clinical relevance of NK cells in cancer immunotherapy.
- 1 February 2003
- Published by Springer Nature in International Journal of Hematology
- Vol. 78 (1) , 7-17
Biology and clinical impact of human natural killer cells
Natural killer (NK) cells, through elaboration of cytokines and cytolytic activity, are critical to host defense against invading organisms and malignant transformation.Two subsets of human NK cells are identified according to surface CD56 expression. CD56dim cells compose the majority of NK cells and function as effectors of natural cytotoxicity and antibody-dependent cellular cytotoxicity, whereas CD56bright cells have immunomodulatory function through secretion of cytokines. For a long time, NK cells have held promise for cancer immunotherapy because, unlike T-lymphocytes, NK cells can lyse tumor cells without tumor-specific antigen recognition.To date, NK cell therapy, largely focused on in vivo expansion and activation with cytokines, has met with only modest success. However, recent understanding of the importance of NK receptors (NKR) for recognition and lysis of tumor cells while normal cells are spared suggests novel therapeutic strategies.The balance of inhibitory and activating signals through surface receptors that recognize major histocompatibility complex class I and class I-like molecules on target cells determines whether NK cells activate killing. Identification of NKR ligands and their level of expression on normal and neoplastic cells has important implications for the rational design of immunotherapy strategies for cancer.We review recent development in the biology and clinical relevance of NK cells in cancer immunotherapy.
- 1 November 2002
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 21 (5) , 1041-1051
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461
Isolated trisomy is a relatively common cytogenetic abnormality in acute myeloid leukemia (AML), but with uncertain prognostic significance. We studied a large cohort of newly diagnosed de novo AML patients karyotyped on CALGB 8461 from 1984-1999, where trisomy was the sole abnormality. The common isolated trisomies (ITC), +8, +11, +13 and +21, comprised 90% of all sole trisomies. The outcome of 101 ITC patients was compared to that of 976 with normal and cytogenetics. The overall survival (OS) for ITC patients was unsatisfactory with 10% [95% confidence interval (CI), 3-17%] alive at 5 years. Repeated cycles of I/HDAC intensification did not improve outcome. However, SCT significantly improved relapse-free survival (RFS). Among ITC patients <60 years in first remission, only 1 of 7 receiving SCT relapsed, compared to 16 of 19 patients treated with chemotherapy only. The prognosis of ITC was dependent on SCT. For non-transplanted patients, the 5-year OS for ITC was 5% (95% CI, 0-11%), compared to 20% (95% CI, 16-23%) for 640 normal cytogenetics patients. ITC was an independent adverse prognostic factor for OS in non-transplanted patients. In those receiving SCT, however, the 5-year OS for ITC patients (69%, 95% CI, 32-100%) was not different to that of transplanted normal cytogenetics patients (60%, 95% CI, 38-81%). We conclude that in de novo adult AML patients not receiving SCT, ITC appears to independently predict a poor outcome that may be improved with SCT in first remission. Prospective studies are required to confirm this hypothesis.
- 1 November 2002
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 21 (5) , 1041-1051
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461
Isolated trisomy is a relatively common cytogenetic abnormality in acute myeloid leukemia (AML), but with uncertain prognostic significance. We studied a large cohort of newly diagnosed de novo AML patients karyotyped on CALGB 8461 from 1984-1999, where trisomy was the sole abnormality. The common isolated trisomies (ITC), +8, +11, +13 and +21, comprised 90% of all sole trisomies. The outcome of 101 ITC patients was compared to that of 976 with normal and cytogenetics. The overall survival (OS) for ITC patients was unsatisfactory with 10% [95% confidence interval (CI), 3-17%] alive at 5 years. Repeated cycles of I/HDAC intensification did not improve outcome. However, SCT significantly improved relapse-free survival (RFS). Among ITC patients <60 years in first remission, only 1 of 7 receiving SCT relapsed, compared to 16 of 19 patients treated with chemotherapy only. The prognosis of ITC was dependent on SCT. For non-transplanted patients, the 5-year OS for ITC was 5% (95% CI, 0-11%), compared to 20% (95% CI, 16-23%) for 640 normal cytogenetics patients. ITC was an independent adverse prognostic factor for OS in non-transplanted patients. In those receiving SCT, however, the 5-year OS for ITC patients (69%, 95% CI, 32-100%) was not different to that of transplanted normal cytogenetics patients (60%, 95% CI, 38-81%). We conclude that in de novo adult AML patients not receiving SCT, ITC appears to independently predict a poor outcome that may be improved with SCT in first remission. Prospective studies are required to confirm this hypothesis.
- Open Access
- 15 September 2002
- Published by American Society of Hematology in Blood
- Vol. 100 (6) , 1935-1947
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Natural killer (NK) cells have held great promise for the immunotherapy of cancer for more than 3 decades. However, to date only modest clinical success has been achieved manipulating the NK cell compartment in patients with malignant disease. Progress in the field of NK cell receptors has revolutionized our concept of how NK cells selectively recognize and lyse tumor and virally infected cells while sparing normal cells. Major families of cell surface receptors that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulinlike receptors (KIRs), C-type lectins, and natural cytotoxicity receptors (NCRs). Further, identification of NK receptor ligands and their expression on normal and transformed cells completes the information needed to begin development of rational clinical approaches to manipulating receptor/ligand interactions for clinical benefit. Indeed, clinical data suggest that mismatch of NK receptors and ligands during allogeneic bone marrow transplantation may be used to prevent leukemia relapse. Here, we review how NK cell receptors control natural cytotoxicity and novel approaches to manipulating NK receptor-ligand interactions for the potential benefit of patients with cancer.
- 15 September 2002
- Published by American Society of Hematology in Blood
- Vol. 100 (6) , 1935-1947
Open AccessNatural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Natural killer (NK) cells have held great promise for the immunotherapy of cancer for more than 3 decades. However, to date only modest clinical success has been achieved manipulating the NK cell compartment in patients with malignant disease. Progress in the field of NK cell receptors has revolutionized our concept of how NK cells selectively recognize and lyse tumor and virally infected cells while sparing normal cells. Major families of cell surface receptors that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulinlike receptors (KIRs), C-type lectins, and natural cytotoxicity receptors (NCRs). Further, identification of NK receptor ligands and their expression on normal and transformed cells completes the information needed to begin development of rational clinical approaches to manipulating receptor/ligand interactions for clinical benefit. Indeed, clinical data suggest that mismatch of NK receptors and ligands during allogeneic bone marrow transplantation may be used to prevent leukemia relapse. Here, we review how NK cell receptors control natural cytotoxicity and novel approaches to manipulating NK receptor-ligand interactions for the potential benefit of patients with cancer.